Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

CDK5 in oncology: recent advances and future prospects.

Lenjisa JL, Tadesse S, Khair NZ, Kumarasiri M, Yu M, Albrecht H, Milne R, Wang S.

Future Med Chem. 2017 Oct;9(16):1939-1962. doi: 10.4155/fmc-2017-0097. Epub 2017 Oct 27. Review.

PMID:
29076761
2.

Mechanism of CDK5/p25 binding by CDK inhibitors.

Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A.

J Med Chem. 2005 Feb 10;48(3):671-9.

PMID:
15689152
3.

Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5.

Arif A.

Biochem Pharmacol. 2012 Oct 15;84(8):985-93. doi: 10.1016/j.bcp.2012.06.027. Epub 2012 Jul 4. Review.

PMID:
22795893
4.

Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.

Kesavapany S, Zheng YL, Amin N, Pant HC.

Biotechnol J. 2007 Aug;2(8):978-87. Review.

PMID:
17526058
5.

Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.

Lacy ER, Wang Y, Post J, Nourse A, Webb W, Mapelli M, Musacchio A, Siuzdak G, Kriwacki RW.

J Mol Biol. 2005 Jun 17;349(4):764-73. Epub 2005 Apr 26.

PMID:
15890360
6.

Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.

Li X, Wang X, Tian Z, Zhao H, Liang D, Li W, Qiu Y, Lu S.

J Mol Model. 2014 Sep;20(9):2407. doi: 10.1007/s00894-014-2407-1. Epub 2014 Aug 21.

PMID:
25142337
7.
8.

An in silico approach for the discovery of CDK5/p25 interaction inhibitors.

Zhang B, Corbel C, Guéritte F, Couturier C, Bach S, Tan VB.

Biotechnol J. 2011 Jul;6(7):871-81. doi: 10.1002/biot.201100139. Epub 2011 Jun 16.

PMID:
21681969
9.

Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.

Kesavapany S, Li BS, Amin N, Zheng YL, Grant P, Pant HC.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):143-53. Review.

PMID:
15023357
10.

Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.

Otyepka M, Bártová I, Kríz Z, Koca J.

J Biol Chem. 2006 Mar 17;281(11):7271-81. Epub 2006 Jan 9.

11.

Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Chatterjee A, Cutler SJ, Doerksen RJ, Khan IA, Williamson JS.

Bioorg Med Chem. 2014 Nov 15;22(22):6409-21. doi: 10.1016/j.bmc.2014.09.043. Epub 2014 Sep 28.

12.

Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.

Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA.

Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.

13.

The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.

Amin ND, Zheng Y, Bk B, Shukla V, Skuntz S, Grant P, Steiner J, Bhaskar M, Pant HC.

Mol Biol Cell. 2016 Nov 1;27(21):3221-3232. Epub 2016 Sep 14.

14.

CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.

Ianes C, Xu P, Werz N, Meng Z, Henne-Bruns D, Bischof J, Knippschild U.

Amino Acids. 2016 Feb;48(2):579-92. doi: 10.1007/s00726-015-2114-y.

PMID:
26464264
15.

Evaluation of the interaction of cyclin-dependent kinase 5 with activator p25 and with p25-derived inhibitor CIP.

Cardone A, Albers RW, Sriram RD, Pant HC.

J Comput Biol. 2010 May;17(5):707-21. doi: 10.1089/cmb.2009.0202.

PMID:
20500023
16.

Cdk5 links with DNA damage response and cancer.

Liu W, Li J, Song YS, Li Y, Jia YH, Zhao HD.

Mol Cancer. 2017 Mar 14;16(1):60. doi: 10.1186/s12943-017-0611-1. Review.

17.

Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.

Xu J, Tsutsumi K, Tokuraku K, Estes KA, Hisanaga S, Ikezu T.

J Neurochem. 2011 Jan;116(2):192-204. doi: 10.1111/j.1471-4159.2010.06824.x.

18.

The role of CDK5/P25 formation/inhibition in neurodegeneration.

Camins A, Verdaguer E, Folch J, Canudas AM, Pallàs M.

Drug News Perspect. 2006 Oct;19(8):453-60. Review.

PMID:
17160145
19.

Inhibition of aberrant cyclin-dependent kinase 5 activity attenuates isoflurane neurotoxicity in the developing brain.

Wang WY, Luo Y, Jia LJ, Hu SF, Lou XK, Shen SL, Lu H, Zhang HH, Yang R, Wang H, Ma ZW, Xue QS, Yu BW.

Neuropharmacology. 2014 Feb;77:90-9. doi: 10.1016/j.neuropharm.2013.09.006. Epub 2013 Sep 18.

PMID:
24055498
20.

Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.

Yousuf MA, Tan C, Torres-Altoro MI, Lu FM, Plautz E, Zhang S, Takahashi M, Hernandez A, Kernie SG, Plattner F, Bibb JA.

J Neurochem. 2016 Jul;138(2):317-27. doi: 10.1111/jnc.13620. Epub 2016 May 25.

Supplemental Content

Support Center